First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen
Many patients with advanced-stage lung cancer cannot tolerate standard platinum-based chemotherapy. As a late-breaking Siow Ming Lee presents the first randomized trial to show that first-line atezolizumab treatment significantly improves overall survival compared to single agent chemotherapy for these poor prognosis patients with no EGFR and ALK alterations.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.